Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1336 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Crescendo designates new CEO

As the chief scientific officer, Romanos has led the formation of the company and the development of its proprietary antibody fragment technologies. Crescendo chairman Clive Dix said that

Syntaxin names new chairman

Most recently, Greig has worked with GlaxoSmithKline’ (GSK) Corporate Venture Group, SR One. Greig has held senior leadership positions in GSK, Advanced Technologies, Rib-X Pharmaceuticals and Anaphore in

Aquinox Pharma starts AQX-1125 Phase 1 trial

Aquinox Pharma’s Phase 1 AQX-1125 is a three part study in healthy volunteers. The primary objectives of Phase I are to evaluate the safety, tolerability and pharmacokinetics of

Merck suspends Ranbaxy research pact

Under the agreement, Ranbaxy was expected to receive around $100m payment from the American drug company, Merck, Economic Times reported. Reportedly, Merck has transferred the research programs to

J&JPRD files Rivaroxaban NDA with FDA

Rivaroxaban is an oral anticoagulant being evaluated for the prevention and treatment of a range of disorders in which blood clotting plays a major role. According to J&JPRD,

Teva Pharma takes over Theramex

Previously, Teva Pharma has signed an agreement with Theramex to take over the distribution rights of Theramex’s products sold in Spain and Brazil and several other countries. Under

Synageva BioPharma in research pact with to-BBB

The companies said that the new collaboration will support the development program of therapies that caters to multiple rare diseases such as, lysosomal storage diseases (LSDs). Synageva R&D

Neogenix gets additional QTDP grant

The grant which is awarded under the Qualifying Therapeutic Discovery Project Program (QTDP) to Neogenix is totaled up to $733,437.74. The company’s NPC-1C (Ensituximab) monoclonal antibody is currently